The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast.

Lewis, Gary D; Haque, Waqar; Farach, Andrew; Hatch, Sandra S; Butler, E Brian; Niravath, Polly A; Schwartz, Mary R; Bonefas, Elizabeth; Teh, Bin S

Lewis, Gary D; Haque, Waqar; Farach, Andrew; Hatch, Sandra S; Butler, E Brian; Niravath, Polly A; Schwartz, Mary R; Bonefas, Elizabeth; Teh, Bin S.

Afiliação

Lewis GD; Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Haque W; Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas, United States.
Farach A; Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas, United States.
Hatch SS; Department of Radiation Oncology, University of Texas Medical Branch, Galveston, Texas, United States.
Butler EB; Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas, United States.
Niravath PA; Department of Clinical Medicine in Oncology, Houston Methodist Hospital, Houston, Texas, United States.
Schwartz MR; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, United States.
Bonefas E; Breast Health Houston, Houston, Texas, United States.
Teh BS; Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas, United States.

Rep Pract Oncol Radiother ; 26(2): 179-187, 2021.

Article em En | MEDLINE | ID: mdl-34211767

Palavras-chave

DCIS; HER2; breast cancer; molecular status; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Rep Pract Oncol Radiother Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google